These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 7718441)

  • 1. Clinical trials referral resource. Prostate cancer II.
    Cheson BD; Phillips PH; Kaplan RS
    Oncology (Williston Park); 1995 Jan; 9(1):50, 55. PubMed ID: 7718441
    [No Abstract]   [Full Text] [Related]  

  • 2. A call for more with a desire for less: pelvic radiotherapy with androgen deprivation in the treatment of prostate cancer.
    Pollack A
    J Clin Oncol; 2003 May; 21(10):1899-901. PubMed ID: 12743140
    [No Abstract]   [Full Text] [Related]  

  • 3. Epothilones and the next generation of phase III trials for prostate cancer.
    Bhandari MS; Hussain M
    BJU Int; 2005 Aug; 96(3):296-302. PubMed ID: 16042717
    [No Abstract]   [Full Text] [Related]  

  • 4. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer.
    Seruga B; Tannock IF
    Nat Clin Pract Oncol; 2008 Oct; 5(10):574-6. PubMed ID: 18628739
    [No Abstract]   [Full Text] [Related]  

  • 5. Specific endothelin-A receptor antagonism for the treatment of advanced prostate cancer.
    Fizazi K; Miller K
    BJU Int; 2009 Nov; 104(10):1423-5. PubMed ID: 19624592
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostate cancer chemotherapy: emerging from the shadows.
    Roth BJ
    J Clin Oncol; 2005 May; 23(15):3302-3. PubMed ID: 15738529
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical trials referral resource. Current phase II and phase III clinical trials in the treatment of colorectal cancer.
    Mooney MM; Schoenfeldt M
    Oncology (Williston Park); 2004 Oct; 18(11):1396, 1401, 1404 passim. PubMed ID: 15609469
    [No Abstract]   [Full Text] [Related]  

  • 8. Twenty-five year evolution of medical hormonal therapy for prostate cancer.
    Moul JW
    BJU Int; 2009 Jan; 103(2):145-6. PubMed ID: 19278531
    [No Abstract]   [Full Text] [Related]  

  • 9. [Interest of the radiotherapy-hormonotherapy association in the treatment of the high-risk prostate cancer].
    Bolla M; Fourneret P; Descotes JL
    Bull Cancer; 2008 Dec; 95(12):1213-8. PubMed ID: 19091656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RTOG clinical trials for prostate cancer.
    DeMare PA
    Hawaii Med J; 2007 Oct; 66(10):273-4, 276. PubMed ID: 18065125
    [No Abstract]   [Full Text] [Related]  

  • 11. Second-line chemotherapy for advanced hormone-refractory prostate cancer.
    Garmey EG; Sartor O; Halabi S; Vogelzang NJ
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):118-22, 127-32. PubMed ID: 18347563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?
    Stadler WM; Michaelis LC; Ratain MJ
    J Clin Oncol; 2005 Nov; 23(31):8124-5; author reply 8125-6. PubMed ID: 16258115
    [No Abstract]   [Full Text] [Related]  

  • 13. Chemotherapy for prostate cancer in senior adults: are we treating the elderly or the frail?
    Bellmunt J
    Eur Urol; 2009 Jun; 55(6):1310-2. PubMed ID: 18778888
    [No Abstract]   [Full Text] [Related]  

  • 14. Other chemotherapy regimens including mitoxantrone and suramin.
    Siu LL; Moore MJ
    Semin Urol Oncol; 1997 Feb; 15(1):20-7. PubMed ID: 9050136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
    Dawson N; Figg WD; Brawley OW; Bergan R; Cooper MR; Senderowicz A; Headlee D; Steinberg SM; Sutherland M; Patronas N; Sausville E; Linehan WM; Reed E; Sartor O
    Clin Cancer Res; 1998 Jan; 4(1):37-44. PubMed ID: 9516950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapies in development for castrate-resistant prostate cancer.
    Harzstark AL; Ryan CJ
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):259-68. PubMed ID: 18279066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
    Vogelzang NJ; Karrison T; Stadler WM; Garcia J; Cohn H; Kugler J; Troeger T; Giannone L; Arrieta R; Ratain MJ; Vokes EE
    Cancer; 2004 Jan; 100(1):65-71. PubMed ID: 14692025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)--outline of pre-clinical and clinical studies].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 2002 Sep; 29(9):1675-87. PubMed ID: 12355959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trials referral resource. Current clinical trials in rhabdomyosarcoma.
    Anderson BD; Schoenfeldt M
    Oncology (Williston Park); 2005 Sep; 19(10):1319-20, 1330. PubMed ID: 16285226
    [No Abstract]   [Full Text] [Related]  

  • 20. An update on randomized clinical trials in localized and locoregional prostate cancer.
    Penson DF
    Urol Oncol; 2005; 23(4):280-8. PubMed ID: 16018945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.